Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.

MLA

Holmsten, Karin, et al. “Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.” JCO Precision Oncology, vol. 8, Oct. 2024, p. e2400209. EBSCOhost, https://doi.org/10.1200/PO.24.00209.

APA

Holmsten, K., Sjödahl, G., Abrahamsson, J., Bernardo, C., Eriksson, P., Höglund, M., Liedberg, F., & Ullén, A. (2024). Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients. JCO Precision Oncology, 8, e2400209. https://doi.org/10.1200/PO.24.00209

Chicago

Holmsten, Karin, Gottfrid Sjödahl, Johan Abrahamsson, Carina Bernardo, Pontus Eriksson, Mattias Höglund, Fredrik Liedberg, and Anders Ullén. 2024. “Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.” JCO Precision Oncology 8 (October): e2400209. doi:10.1200/PO.24.00209.